Date: 2017-11-10
Type of information: Nomination
Compound: vice president strategic business development
Company: Medivir (Sweden)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 10, 2017, Medivir announced the appointment of Christina Herder, as Executive Vice President, Strategic Business Development effective December 14, 2017. Christina will report to CEO Christine Lind and will join Medivir’s executive management team.
- The addition of Christina at Medivir fills an important role focusing in the near-term on out-licensing of Medivir’s projects that could benefit from the capabilities of a partner, whether at late stages of clinical development or early stages of research. Christina will also be responsible for leading any in-licensing or acquisition of projects that are synergistic with Medivir’s scientific areas of expertise, as well as managing alliances with existing partners.
- Christina has 25 years experience of supporting drug development in the areas of corporate and business development, strategy and project management. Her most recent employment was as CEO of Modus Therapeutics. Prior to Modus, Christina held various leadership positions at Sobi AB (and previously Biovitrum), including in Corporate Development, Licensing, and Portfolio and Project Management. She began her career at Pharmacia & Upjohn. Christina earned a PhD in Physical Chemistry from the Royal Institute of Technology from KTH in Stockholm, and holds an MBA from Stockholm University.
Financial terms:
Latest news:
Is general: Yes
